Valeant

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

Valeant Receives Non-Approvable Letter from FDA for Labeling Application of Cannabinoid Cesamet™

COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has received a non-approvable letter from the U.S. Food and Drug Administration for the company's application requesting labeling changes to its previously approved drug Cesamet CII nabilone. The FDA requested additional information to address concerns over potential class...

Tags: FDA, Valeant

Research articles 2005-12-30

Life Without Blockbusters: What Valeant's Woes Portend for Pharma

It's now a truism that the drug industry's "blockbuster model" has pretty much had its day. Much of Big Pharma is having a terrible time winning approval for new drugs and even keeping up sales of existing blockbusters, in part because their underlying rationale -- that pushing drugs into mass...

Tags: Pharmaceutical Company, Blockbuster, Drug, Valeant, David P. Hamilton

Blog posts 2008-05-05

Additional Resources

Valeant Pharmaceuticals and GlaxoSmithKline Announce Worldwide Collaboration Agreement for Retigabine

* Retigabine is a potentially significant advance for treatment of epilepsy * GSK to make upfront payment to Valeant of $125 million * Valeant to share up to 50 percent of net profits in U.S., Canada, Australia, New Zealand and Puerto Rico and receive up to...

Articles 2008-08-28

Retigabine Agreement Can Give Meda Significant Royalty Income

STOCKHOLM, Sweden -- Regulatory News: The pharmaceutical company GlaxoSmithKline has signed an exclusive worldwide collaboration agreement with Meda's (STO:MEDAA) partner Valeant Pharmaceuticals for the Retigabine substance. Meda is entitled to receive significant royalties and certain milestone payments. Retigabine comprises a new way of affecting potassium channels...

Articles 2008-08-28

Valeant Pharmaceuticals to Present at UBS Global Life Sciences Conference

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that members of its senior management team will make a presentation at the UBS Global Life Sciences Conference on Wednesday, September 24, 2008 at 11:00 a.m. EDT. The conference will be held at The Grand Hyatt Hotel in New...

Articles 2008-08-22

Meda Acquires European Businesses from American Valeant and Enters the Russian Market

-- Meda acquires Valeant's pharmaceutical business in Western andEastern Europe- Consistent step in Meda's growth strategy- Sales level of 1 100 MSEK- Organisation of 380 employees-- Meda gains- Russian entry with own organisation- Significant market synergies in Eastern Europe- Strengthened position in Western Europe, especially in the UK- Enhanced position...

Articles 2008-08-04

Valeant Sells Certain Business Operations in Europe for $392 Million

* Operations in Western Europe, Eastern Europe including Russia, and certain export markets had approximately $180 million in 2007 annual revenues * Central Europe operations not included in the transaction ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that it had agreed to sell...

Articles 2008-08-04

Swedish pharmaceuticals marketing company Meda AB acquires European operations of US group Valeant

NORDIC BUSINESS REPORT-4 August 2008-Swedish pharmaceuticals marketing company Meda AB acquires European operations of US group ValeantC1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com Swedish speciality pharmaceuticals company Meda AB (OMX Stockholm: MEDA A) said on Monday (4 August) that it has agreed to acquire the European operations of the US...

Articles 2008-08-04

Amneal Pharmaceuticals

Amneal Pharmaceuticals recently received approval from the Food and Drug Administration to manufacture three generic drugs: primidone 50 mg and 250 mg; cyclobenzaprine 10 mg; and demeclocycline 150 and 300 mg. Demeclocycline is the generic version of Stonebridge Pharma's Declomycin, which is used to treat infections caused by...

Articles 2008-07-21

Comprehensive Evaluation of the UK Pharmaceutical Manufacturers Market

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/76d7a6/pharmaceutical_man) has announced the addition of the "Pharmaceutical Manufacturers UK - Portfolio Analysis" report to their offering. The Plimsoll Portfolio Analysis - Pharmaceutical Manufacturers is a comprehensive evaluation of the UK market. The revised and updated 2008 edition analyses...

Articles 2008-07-02

ABT is the Only Source for Kelo-cote® Advanced Formula Scar Gel

CLEARWATER, Fla., June 25 /PRNewswire/ -- Kelo-coteR advanced formula scar gel is a unique patented silicone formula using cross-link technology and has become the gold standard for scar treatment and abnormal scar prevention. The patented silicone formula in Kelo-coteR advanced formula scar gel is ONLY available...

Articles 2008-06-25

Valeant Announces Redemption of All Outstanding 7% Senior Notes Due 2011

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that it will redeem all of the $300 million aggregate principal amount outstanding of its 7% Senior Notes due 2011 (CUSIP No. 91911XAG9) (the "Notes"). On June 20, 2008, a copy of the irrevocable...

Articles 2008-06-20

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares™ Indexes

NEW YORK, June 17 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the quarterly rebalancing of the Indexes. The following securities will be added and deleted in the Indexes effective before...

Articles 2008-06-17

Valeant Pharmaceuticals Announces Increase in Share Repurchase Authorization

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that its board of directors has authorized the repurchase of an additional $100 million of its outstanding common stock under its 2007 stock repurchase program. This repurchase authorization raises the aggregate repurchase authorization to $300 million...

Articles 2008-06-17

Valeant Pharmaceuticals Divests Argentina

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that it has divested its Argentina commercial operations to one of the leading pharmaceutical companies in Argentina. Financial terms were not disclosed. "One of our strategic initiatives for 2008 is to divest certain regions and...

Articles 2008-06-10

Senetek PLC Announces Key Personnel Appointments

Phillip Rose Named Chief Operating Officer NAPA, Calif., June 9 /PRNewswire-FirstCall/ -- Senetek PLC (BULLETIN BOARD: SNKTY) , a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that the Company has appointed Veteran...

Articles 2008-06-09

Valeant Pharmaceuticals to Present at Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE: VRX) today announced members of its senior management team will make a presentation at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference on Thursday, June 12, 2008 at 8:00 a.m. PDT. The conference will be held at The Ritz-Carlton Laguna Niguel, Dana...

Articles 2008-06-04

Pipeline previews

Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatological community. These features may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new products. In addition,...

Articles 2008-06-01

Valeant Pharmaceuticals to Webcast 2008 Annual Meeting of Stockholders

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it will conduct a live webcast of the company's annual meeting of stockholders. The meeting and webcast will be held on Tuesday, May 20, 2008 at 9:00 a.m. PDT. A live webcast and audio archive of the...

Articles 2008-05-19

Valeant Pharmaceuticals Announces FDA Has Initiated Reconsideration of Generic Efudex® Approval

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals (NYSE:VRX) today announced that the Food and Drug Administration the FDA has entered an administrative order "in the public interest" to stay the approval of generic fluorouracil cream 5% until May 30, 2008 "because there are outstanding questions regarding this approval that the Agency...

Articles 2008-05-15